Company: PACB
Filing Date: 2025-03-17
Form Type: 10-K
Source: 0001299130-25-000061
Chunk: 147

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-03-17
Form: 10-K
Item: Item 1
Chunk 147
---
 602 (180)334,561 Total cash, cash equivalents, and investments $389,509 $602 $(180)$389,931 Short-term restricted cash$690 $— $— $690 Long-term restricted cash$1,532 $— $— $1,532 December 31, 2023(in thousands)AmortizedCostGrossunrealizedgainsGrossunrealizedlossesFairValueCash and cash equivalents:Cash and money market funds$70,172 $— $— $70,172 Commercial paper — — — — U.S. government & agency securities109,786 13 (60)109,739 Total cash and cash equivalents 179,958 13 (60)179,911 Investments:Commercial paper 9,947 — — 9,947 Corporate debt securities 88,263 373 (57)88,579 U.S. government & agency securities353,029 478 (528)352,979 Total investments 451,239 851 (585)451,505 Total cash, cash equivalents, and investments $631,197 $864 $(645)$631,416 Short-term restricted cash$300 $— $— $300 Long-term restricted cash$2,422 $— $— $2,422 The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of December 31, 2024:(in thousands)Fair ValueDue in one year or less $238,957 Due after one year through 5 years 95,604 Total investments $334,561 Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.

Fiscal 2024 Form 10-K102

Investment income included in other income, net on our consolidated statements of operations and comprehensive loss was $24.9 million and $32.8 million for the years ended December 31, 2024 and 2023, respectively.

NOTE 4.  BALANCE SHEET COMPONENTS Inventory, NetInventory, net, consisted of the following components:December 31,(in thousands)20242023Purchased materials$45,270 $32,434